ANNX Annexon Accounting Capitalization

Annexon, Inc. (ANNX) focuses on the final scaling phase of advanced complement system inhibition therapies. Management is effectively allocating investments to accelerate the validation of neurology and ophthalmology drugs. The business relies on external contractors for substance synthesis and testing, and the 0.19 metric is visible on the price chart illustrating cost trends on the GURU.Markets platform.

ANNX Annexon Book Capitalization (07/04/2022 - 10/27/2026)

Metric breakdowns and analytics for Annexon (ANNX)

- price and consensus price forecast:

Share Price Annexon Biosciences Inc.|ANNX - Consensus Target

- market capitalization data:

Market Capitalization Annexon, Inc.|ANNX - Total Company Value

- book capitalization data:

Equity per Share Annexon|ANNX - Book Capitalization|Market-to-Book Ratio annexonbio.com|ANNX - Cumulative Company Assets

- debt and liquidity data:

Total Debt to Capital Annexon, Inc.|ANNX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Annexon Biosciences|ANNX - Company Debts|Debts to Book Value Annexon, Inc.

Summary company analysis:ANNX - Annexon Biosciences Inc.

Flagship merchandise of Annexon Biosciences

The scale of operations for Annexon, Inc. (ANNX) is determined by the value of its intellectual assets within the biotechnology sector. Book capitalization synthesizes reporting data with the market share price to measure the real value of equity. Investors decouple fundamental strength from market noise by analyzing the impact of debt load on capital. Given the non-cyclical nature of drug development, this metric demonstrates recession resilience. This chart of book capitalization movement confirms the internal stability of the business.

Competitor analysis for Annexon, Inc.

Biogen Idec (BIIB) - Accounting Capitalization|Company Net Assets Neurocrine Biosciences|RGC (regencellbioscience.com) - Accounting Capitalization|Company Book Value Axsome Therapeutics, Inc. (AXSM)|Accounting Capitalization ACADIA Pharma|Xenon Pharmaceuticals Inc - Book Capitalization|Total Stockholders' Equity Viking Therapeutics Corp VKTX|Company Net Assets SUPN (Supernus Pharmaceuticals)|catalystpharma.com - Book Capitalization|Company Book Value Denali Therapeutics Inc. (DNLI)|HRMY: Accounting Value of Company|Company Book Value BHVN|Amylyx Corp (AMLX) - Total Stockholders' Equity|TRVI (Trevi Therapeutics) - Book Capitalization|Book Capitalization PRAX|Company Book Value Anavex Life Sciences Corp. AVXL|Accounting Capitalization CBLL (CeriBell Inc)|PRTA - Company Book Value|Accounting Capitalization Alector Inc. ALEC|OMER (Omeros Corp.) - Book Capitalization|neurogene.com (NGNE) - Total Stockholders' Equity|Company Net Assets AC Immune SA|VYGR (Voyager Therapeutics Inc) - Accounting Capitalization|Company Book Value NMRA (Neumora Therapeutics Inc)|Total Stockholders' Equity SCLX|Company Book Value Tevogen Bio Holdings TVGN|Accounting Capitalization alphacognition.com ACOG|Company Net Assets Cognition Therapeutics|Accounting Value of Company Inhibikase Therapeutics Inc IKT|Book Capitalization SAVA (Cassava)|ASRT: Book Valuation of Business|Company Book Value coyatherapeutics.com|Vistagen (VTGN) - Accounting Capitalization|Book Capitalization OVID|Company Net Assets Acumen Pharmaceuticals Inc. (ABOS)|CRVO (CervoMed Inc) - Company Net Assets|Book Valuation of Business alteritytherapeutics.com (ATHE)|Book Capitalization CLNN (Clene)|PepGen Inc - Book Capitalization|Jupiter Neurosciences Inc (JUNS) - Company Book Value|RLMD: Accounting Capitalization|Company Book Value Annovis Bio Corp|Accounting Capitalization Grace Therapeutics|Company Net Assets Firefly Neuroscience, Inc (AIFF)|Accounting Capitalization KLTO|Company Book Value NeuroSense Therapeutics NRSN|Accounting Capitalization Reviva Pharmaceuticals Holdings Inc. (RVPH)|MTVA: Book Capitalization|NRXS - Total Stockholders' Equity|Helius Medical Technologies Inc. - Company Net Assets|PASG: Book Capitalization|Company Book Value bionomics.com.au NEUP|NERV (Minerva Neurosciences Inc) - Accounting Value of Company|Company Book Value ATHA (Athira)|Total Stockholders' Equity Addex|Book Capitalization ALZN|Book Capitalization CYCN (cyclerion.com)|PTIX - Company Book Value|Pasithea Therapeutics Corp - Accounting Capitalization|Cortigent Medical (CRGT) - Company Book Value|ATXI - Accounting Capitalization|Book Capitalization BCLI|Total Stockholders' Equity caratherapeutics.com|Company Net Assets Chromocell Therapeutics Corp. (CHRO)|Accounting Capitalization ELYM|Intra-Cellular Therapies - Company Book Value|Total Stockholders' Equity LBPH (Longboard)|MRNS - Company Book Value|NKGN - Accounting Capitalization|Company Net Assets NeuroBo Pharmaceuticals, Inc. (NRBO)|SAGE - Accounting Value of Company|Neurotrope - Book Capitalization|TRVN (Trevena Inc) - Book Valuation of Business|Company Book Value Vigil Neuroscience Inc. (VIGL)|Accounting Capitalization Anew Medical Inc.|Book Capitalization CERE (Cerevel Therapeutics, Inc.)